EB01 (daniluromer)

About Edesa Biotech

Edesa Biotech is a micro-cap, clinical-stage biotech focused on developing targeted therapies for inflammatory and immune-related diseases, with a dual strategy in acute care and chronic dermatology. Its most advanced assets include EB05, a Phase 3-ready monoclonal antibody for acute lung injury, and EB01, a Phase 2b non-steroidal topical cream for chronic allergic contact dermatitis. The company's strategy is to achieve clinical proof-of-concept and seek strategic partnerships or out-licensing agreements to advance its programs. Despite a challenging financial position, its pipeline addresses significant unmet medical needs with novel mechanisms.

Therapeutic Areas